Infant Bacterial Therapeutics Advances IBP-9414 Toward Accelerated Approval

Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has issued an announcement.

Infant Bacterial Therapeutics reported key 2025 milestones in the development of its lead candidate IBP-9414 for premature infants. The U.S. Food and Drug Administration granted IBP-9414 Breakthrough Therapy Designation in March based on its potential to reduce gastrointestinal-related mortality, underscoring the therapy’s clinical relevance and regulatory momentum.

In May, the company submitted the Phase 3 Clinical Study Report to the FDA, and in November it chose to pursue an accelerated approval pathway for IBP-9414. During the fourth quarter, it also secured manufacturing partnerships with Recipharm Advanced Bio and BioConnection, strengthening its supply chain and readiness for potential commercialization.

The most recent analyst rating on ($SE:IBT.B) stock is a Hold with a SEK48.00 price target. To see the full list of analyst forecasts on Infant Bacterial Therapeutics AB stock, see the SE:IBT.B Stock Forecast page.

More about Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB is a biopharmaceutical company focused on developing microbiome-based therapies to address unmet medical needs in premature infants. Its lead product candidate, IBP-9414, targets gastrointestinal complications and mortality in this highly vulnerable neonatal population.

Average Trading Volume: 6,173

Technical Sentiment Signal: Sell

Current Market Cap: SEK656.1M

See more insights into IBT.B stock on TipRanks’ Stock Analysis page.